Rewriting the Rules of Psychiatry Drug Development: Measurement, Psychedelics and the Future of CNS Strategy
Explore how measurement innovation, psychedelic development and value strategy are reshaping psychiatric drug development and CNS clinical trials.
Psychiatric drug development and CNS clinical trials have historically faced high failure rates, measurement variability and commercial uncertainty. Today, advances in AI-enabled clinical measurement, psychedelic therapies and regulatory engagement are reshaping how sponsors design, execute and position neuroscience programs.
This Insights Hub white paper synthesizes expert perspectives from the 2025 CNS Summit podcast series, examining how innovation in measurement, operational rigor and value articulation is influencing modern CNS development strategy.
In this download, you’ll explore:
- How subjective endpoints in psychiatry impact signal detection and investor confidence
- The role of AI-powered rater training and multimodal data in strengthening CNS clinical trial measurement
- Operational considerations for advancing psychedelic therapies through Phase III and regulatory review
- Why regulatory alignment and execution discipline are critical in emerging CNS programs
- How sponsors can reframe value in psychiatry to address long-term healthcare and societal impact
Designed for biotech executives, clinical development leaders and regulatory stakeholders, this paper provides practical insight into integrating clinical, regulatory, commercial and value strategy in CNS drug development.
Download the full white paper to explore how stronger measurement, disciplined execution and strategic value articulation can support more credible and sustainable psychiatric drug development programs.
Related Content
Looking for exclusive insight?
